Division of Cardiology, "Tor Vergata" University Hospital, Viale Oxford 81, 00133 Rome, Italy.
Department of Experimental Medicine, University "Tor Vergata", 00133 Rome, Italy.
Int J Mol Sci. 2023 Jul 1;24(13):10979. doi: 10.3390/ijms241310979.
Atherosclerotic cardiovascular disease is the most common cause of morbidity and death worldwide. Recent studies have demonstrated that this chronic inflammatory disease of the arterial wall can be controlled through the modulation of immune system activity. Many patients with cardiovascular disease remain at elevated risk of recurrent events despite receiving current, state-of-the-art preventive medical treatment. Much of this residual risk is attributed to inflammation. Therefore, finding new treatment strategies for this category of patients became of common interest. This review will discuss the experimental and clinical data supporting the possibility of developing immune-based therapies for lowering cardiovascular risk, explicitly focusing on vaccination strategies.
动脉粥样硬化性心血管疾病是全世界发病率和死亡率的最常见原因。最近的研究表明，这种动脉壁的慢性炎症性疾病可以通过调节免疫系统的活性来控制。尽管接受了目前最先进的预防医学治疗，但许多心血管疾病患者仍然存在复发事件的高风险。这种残余风险在很大程度上归因于炎症。因此，为这一类患者寻找新的治疗策略成为共同关注的问题。本综述将讨论支持为降低心血管风险开发基于免疫的治疗方法的实验和临床数据，特别关注疫苗接种策略。
